Kits Eyecare’s Deliberate Glasses Pivot Pays Off in Q2: Higher AOV, Record Cash Flow, and a H2 Rebalance
The vision care platform trades near-term revenue growth for higher-value glasses cohorts, then refocuses on its contact-lens annuity.
KITS.TO · Earnings Call · 2026-08-05
The Glasses Inflection
Kits Eyecare’s second quarter was a study in deliberate trade-offs. Revenue grew 7.8% year-over-year to $58.4 million, but that was a deceleration from Q1’s pace — a cost the company accepted to fuel its glasses customer acquisition engine. The glasses business reached $11.1 million, up 54%, now representing almost 19% of revenue. More telling, premium lens upgrades hit 45.2% of glasses revenue, and new glasses customers spent 50% more on first orders than the same cohort a year ago, on identical entry-level pricing. As CEO Roger Hardy put it: “Not one thing did that, but customers are taking more pairs. They're upgrading their lenses. They're buying into categories we've added like progressive readers and anti-fatigue lenses…” — Roger Hardy, Chief Executive Officer · 2026-08-05 The momentum in anti fatigue lenses is particularly notable. COO Joseph Thompson highlighted the Q2 launch: “In Q2, we launched anti-fatigue lenses designed to reduce ice rain during screen time and close up work.” — Joseph Thompson, Chief Operating Officer · 2026-08-05 This new product adds to an already rich premium lens portfolio, and management sees “a lot of runway ahead” for further expansion. The average order value climbed 15.8% to $213, driven by multi-pair, progressives, and premium add-ons — all without raising base prices.Balance-Sheet Firepower
Beyond the product mix, the quarter’s real standout was cash generation. Operating cash flow hit a record $7.8 million, roughly 2.7x adjusted EBITDA, and free cash flow was $6.4 million. CFO Ibrahim Kamar noted: “We ended the quarter with $27.4 million in cash, up from $19 million at the end of Q1 and zero debt, including our fully undrawn $15 million ABL facility with the Bank of Montreal…” — Ibrahim Kamar, Chief Financial Officer · 2026-08-05 The company even repurchased 89,200 shares for $1 million under its NCIB. This financial strength is a direct result of the cash generation embedded in the recurring contact-lens annuity and now amplified by the higher-margin glasses mix. While the global tape buzzes with IEEPA refunds, Kits explicitly called its 160 basis-point gross-margin expansion organic, with no tariff benefit — a sign of durable vertical integration.Rebalancing for H2
The strategic plan is explicit: rebalance acquisition spend back to contact lenses in the second half while glasses momentum becomes increasingly organic. As Hardy stated:That’s a crucial acknowledgment that the contact-lens engine remains the core annuity. The company guided Q3 revenue to $62–64 million with adjusted EBITDA margin of 4–6%, expecting both engines to run. The Toronto store on Queen Street West opened late in Q2, already performing above expectations, and the Manulife insurance partnership adds another 7 million potential customers. These moves are part of a longer-term “Own This Town” strategy that has been building for over a year. Comparing to prior quarters, the company’s enthusiasm for glasses is not new — it’s been a persistent theme. But the depth of the pivot, with glasses AOV up 60% and the decision to temporarily sacrifice overall growth, marks a notable escalation. In the Q1 call, Roger described the flywheel: “we're seeing the lifetime value compound. And that's the exciting piece of the business. We're combining customer growth with increasing lifetime value.” — Roger Hardy, Chief Executive Officer · 2026-03-04 Now that compounding is showing up in the P&L — repeat revenue reached 65.5% of the mix, and the active customer base grew 15% to over 1.1 million. Overall, Kits Eyecare is executing a high-conviction strategy: invest now in higher-value glasses customers, fund it with record cash flow, and rebalance later. The story hinges on whether those cohorts indeed deliver the promised LTV, but the early evidence — rising AOV, premium take-rates, and a fortified balance sheet — is hard to argue with.In the back half, we plan to rebalance. We will keep the glasses momentum, which is increasingly organic, driven by cross-sell and repeat purchasing and we'll put the full weight of acquisition back behind contact lenses which remains the most proven customer generation engine we have and the front door through which most kids relationships begin.